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Abstract: Lung ischemia reperfusion (IR) injury inevitably occurs during lung transplantation. The
pulmonary endothelium is the primary target of IR injury that potentially results in severe pulmonary
dysfunction. Over the last decades, various molecules, receptors, and signaling pathways were identified
in order to develop treatment strategies for the preservation of the pulmonary endothelium against IR
injury. We here review the latest and most promising therapeutic strategies for the protection of the
endothelium against IR injury. These include the stabilization of the endothelial glycocalyx, inhibition of
endothelial autophagy, inhibition of adhesion molecules, targeting of angiotensin-converting enzyme, and
traditional viral and novel non-viral gene transfer approaches. Though some of these strategies proved to
be promising in experimental studies, very few of these treatment concepts made the transfer into clinical
application. This dilemma underscores the need for more experimental evidence for the translation into
clinical studies to invent therapeutic concepts against IR injury-mediated endothelial damage.
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Lung ischemia reperfusion (IR) injury inevitably occurs during lung transplantation. The
pulmonary endothelium is the primary target of IR injury that potentially results in
severe pulmonary dysfunction. Over the last decades, various molecules, receptors,
and signaling pathways were identified in order to develop treatment strategies for
the preservation of the pulmonary endothelium against IR injury. We here review the
latest and most promising therapeutic strategies for the protection of the endothelium
against IR injury. These include the stabilization of the endothelial glycocalyx, inhibition
of endothelial autophagy, inhibition of adhesion molecules, targeting of angiotensin-
converting enzyme, and traditional viral and novel non-viral gene transfer approaches.
Though some of these strategies proved to be promising in experimental studies, very
few of these treatment concepts made the transfer into clinical application. This dilemma
underscores the need for more experimental evidence for the translation into clinical
studies to invent therapeutic concepts against IR injury-mediated endothelial damage.
Keywords: lung, transplantation, ischemia-reperfusion injury, endothelium, strategies
INTRODUCTION
Ischemia reperfusion (IR) injury in lung transplantation (Tx) is associated with an increased rate
of delayed graft function, but also acute and chronic graft rejection. As IR injury is unavoidably
correlated with Tx, treatment strategies for the attenuation of IR injury should aim at protecting
target compartments that are primarily affected by IR injury.
The pulmonary endothelium is the first site of IR injury. Already during organ ischemia,
multiple donor-associated changes can alter the status of the pulmonary vasculature, that is e.g.,
the loss of surfactant, hypovolemia resulting in platelet occlusion of the vascular bed, an increase of
pro-inflammatory mediators due to brain death, and an increase of adhesion molecules (Porteous
and Lee, 2017). Upon reperfusion, the endothelial layer of the pulmonary vasculature produces
reactive oxygen species (ROS) and other damaging agents (Preissler et al., 2011) which in turn
results in endothelium swelling and detachment from the basement membrane (Pickford et al.,
1990). This process results in a damage of the vascular permeability thereby facilitating leukocyte
adherence and transmigration, the key step in mediating IR injury (Soroush et al., 2018). The
interaction between leukocytes and endothelium depends on and involves a complex network of
various proteins.
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Over the last decades, a wide range of those proteins have
been identified that mediate the differential steps necessary for
the interaction between white blood cells and endothelium.
Among them, selectins are responsible for a first contact and
weak adhesion of leukocytes (Kawut et al., 2009), different
adhesion molecules create a firmer contact of leukocytes on the
endothelium and leukocyte extravasation across the endothelial
wall (Muller, 2016), and finally the migration of leukocytes
into the tissue is mediated by IL-8 and other mediators (Allen
and Kurdowska, 2014). A number of other mediators such
as TNFα, IL-1, IL-6, leukotriene B4, proteases, and elastases
that are in part released from activated neutrophils, indirectly
or directly, contribute to endothelial dysfunction and injury
(Porteous and Lee, 2017).
Another target of IR that contributes to endothelial damage
and tissue dysfunction after IR is the endothelial glycocalyx. This
layer consists of proteoglycans and glycoproteins at the surface
of the endothelium and harbors various chemokines, receptors,
growth factors, and enzymes that play a central role in endothelial
function. The endothelial glycocalyx has a pivotal importance in
lung injury which has been shown during edema formation after
lung IR injury when the integrity of the glycocalyx was damaged
(Brettner et al., 2017).
During the last decades of research, many of these proteins,
receptors, mediators, and inflammatory cascades participating in
endothelial injury upon IR injury have been targeted by treatment
strategies, either by antibodies, inhibitors, or modulators of the
inflammatory milieu. Among these, older agents include the
phosphodiesterase inhibitor cyclic AMP analog or nitride oxide.
We here will present and discuss the most recent and
promising developments on strategies how to efficiently preserve
the endothelium from lung IR injury.
An Ambiguous Role for Autophagy
Inhibition on Pulmonary Endothelium
During IR Injury
Autophagy allows for the regular degradation and recycling of
cellular components and thus promotes cell survival. However,
upon injury, an imbalance in endosomal and autophagic
pathways can enhance macromolecular or organelle degradation
thereby causing cell death. Inhibition of autophagy was shown
to result in reduced apoptosis indicating that the process of
autophagy as a cell survival mechanism is rather endangering the
lung during IR injury (Zhang et al., 2013). On the other hand,
recent analyses on pulmonary microvascular endothelial cells
exposed to hypoxia-reoxygenation revealed that the suppression
of mitochondrial autophagy by 3-Methyladenine (3-MA), a
selective PI3K inhibitor, inhibited the apoptosis of endothelial
cells and enhanced its proliferation via the mechanistic Target
of Rapamycin-pathway (Liu et al., 2019). Another study in
human and mouse pulmonary microvascular endothelial cells
convincingly showed that promoting autophagy with rapamycin
ameliorated IR-induced lung edema and tissue inflammation due
to injured endothelium (Zhang et al., 2015).
Taken together, research on targeting autophagy has so far
been scarce and results presented seem to be ambiguous, so there
is a clear need for more studies that proves an either endothelial-
preserving or endothelial-damaging effect of autophagy.
Stabilization of the Endothelial
Glycocalyx From Degradation by Lung
I/R Injury
The luminal surface of vascular endothelial cells is lined with
a glycocalyx, comprising of membrane-bound proteoglycans,
glycosaminoglycans, and sialic acid–containing glycoproteins.
This layer is pivotal for the integrity and functionality of the
endothelium, as it modulates the interaction of the endothelium
with the components of the circulating blood. The glycocalyx
harbors a variety of chemokines, receptors, growth factors, and
enzymes that play a central role in endothelial function. This
layer protects the endothelium from shear stress which is caused
by blood flow and serves as a vascular permeability barrier.
Glycocalyx damage during IR can be detected by elevated plasma
levels of e.g., heparan sulfate and syndecan-1, which suggests
their use as biomarkers of endothelial integrity (Abassi et al.,
2020) (Figure 1).
The glycocalyx of the pulmonary vasculature is thicker than
that of other organs (Yang and Schmidt, 2013) which might be
owed to the complex lung defense against internal and external
antigens. During and after lung IR, the glycocalyx is degraded
and leads to leukocyte activation and adhesion with subsequent
pulmonary edema and lung injury. Experimental studies showed
that the integrity of the glyocalyx layer could be preserved: e.g., in
an auto-transplantation model, Rancan et al. (2018) could show
that IR itself causes glycocalyx alterations with an increase in
pulmonary edema and expression of adhesion molecules, and
that by the administration of lidocaine, the described alterations
of glycocalyx degradation could be abolished (Figure 1). The
same research group proved in an in vivo auto-transplantation
model of pulmonary IR that by preconditioning with sevoflurane,
the pulmonary glycocalyx could be protected and the expression
of leukocyte chemokines could be reduced (Casanova et al.,
2016). In this study, authors compared the effects of sevoflurane
with propofol on IR-injured endothelium and found that
propofol, but not sevoflurane, induced glycocalyx destruction
and a higher chemokine and adhesion molecule expression
with also an increase of the glycocalyx components heparan
sulfate and serum syndecan levels (Casanova et al., 2016). Work
from Chappell et al. also revealed less shedding and a reduced
leukocyte adhesion after sevoflurane pre-treatment in an isolated
organ model (Chappell et al., 2010). In contrast, another group
analyzed those endothelial glycocalyx-injuring markers heparan
sulfate and human syndecan-1 in patients undergoing pulmonary
resection with one lung ventilation, however, they could not find
any difference in outcome between sevoflurane and propofol
(Kim et al., 2018).
As reflected by increased research activity in recent years,
the glycocalyx has gained more attention taking a pivotal
role in the regulation of endothelial function and vascular
permeability. Though the number of studies is limited,
glycocalyx components such as syndecan-1 and heparan
sulfate have the potential to serve as circulatory biomarkers
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FIGURE 1 | Endothelial glycocalyx degradation induced by ischemia-reperfusion injury and its restoration by Lidocaine and Sevoflurane. Upon IR injury, free radicals,
among others, contribute to glycocalyx erosion. IR injury also leads to activation of leukocytes that in turn increase the secretion of chemokines and adhesion
molecules, all damaging the endothelial layer. Heparan sulfate and syndecan-1 are shed into the blood when the glycocalyx is damaged by IR and could function as
biomarkers of endothelial integrity. Both Lidocaine and Sevoflurane can restore and preserve damaged glycocalyx. IR, ischemia-reperfusion.
FIGURE 2 | Mediators and strategies to protect the vascular endothelium from lung IR injury. Endothelial immunotargeting by a catalase-binding antibody to the
angiotensin-converting-receptor on endothelium can reduce IR-reactive oxygen species. Erythropoietin exerts protective functions on endothelial cells by preventing
apoptosis via endothelium-bound EPO receptors. Diannexin V mainly acts via preventing endothelial cell adhesion, and Kalium ATP-sensitive (ATP-sensitive
potassium channels, KATP) channel agonists have the potential to prevent membrane depolarization thereby protecting the endothelium. Gene transfer of siRNA to
the endothelium can reduced apoptosis, less production of adhesion molecules, and a reduced attraction of neutrophils. Finally, antibody-conjugated
endothelial-targeted liposomes can inhibit the cytokine-induced inflammatory activation of the endothelium. IR, ischemia-reperfusion; ACE, angiotensin-converting
enzyme; EPO, Erythropoetin; KATP, Kalium ATP-sensitive; siRNA, small interfering ribonucleic acid.
for monitoring the severity of vascular endothelial damage
during lung IR injury. Moreover, future research on glycocalyx
protection and restoration has so far received a solid base,
and pharmacologic and non-pharmacologic maneuvers
on this topic should be promoted. Figure 1 provides an
overview of the current understanding of the glycocalyx in
the context of IR injury and its preservation by Lidocaine
and Sevoflurane.
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FIGURE 3 | Viral and non-viral approaches to preserve IR-injured lung endothelium. One of the most commonly employed viral vectors is the adeno-associated
virus. By such a virus, silicon microparticles can be delivered into inflammation-associated endothelium where it is internalized with the subsequent release of
therapeutic nanoparticles. The virus becomes free within the cytoplasm, undergoes genetic cargo, and transfers into the nucleus for the transcription of
endothelium-protective mediators. In contrast, non-viral approaches have advantages over the commonly used viral systems such as lower immunogenicity,
reduced inflammation, and an overall better safety. A human Indoleamine-2,3-dioxygenase (IDO)–expressing plasmid can be delivered by a specific promoter into the
endothelium and reduces cell apoptosis, vascular permeability, and leukocyte extravasation. Moreover, the mitochondrial function and ultrastructure of the
endothelium is protected from oxidative stress. IDO, Indoleamine-2,3-dioxygenase.
Targeting P-selectin on I/R-Injured
Pulmonary Endothelium
Selectins are molecules involved in the initial process of adhesion
of activated neutrophils on the pulmonary endothelium. Early
work has shown that when selectively blocking selectins with
a monoclonal antibody, reperfusion-induced hyperpermeability
was ameliorated (Demertzis et al., 1999; Levine et al., 2002). More
recently, a particular role has been assigned to P-selectin in IR
injury (Moore et al., 1985; Scalia et al., 1999). As a key endothelial
cell rolling factor, P-selectin mediates the adhesion of leukocytes
on the endothelium and binds to glycoprotein ligand-1 (PSGL-1)
on leukocytes. Moore et al. (1985) showed that when inhibiting
P-selectin by a monoclonal antibody, the increase of IR-induced
permeability, lung sequestration of neutrophils, mononuclear
leukocytes, and eosinophils could be significantly attenuated.
But also the rolling and adhesion of platelets along arteriolar
walls depends on P-selectin, suggesting that platelets are also
responsible for contributing to the development of pulmonary
IR injury (Roberts et al., 2004). In line with these data, recent
work from Lam et al. (2018) confirmed the role of P-Selectin
in interaction with PSGL-1 in the attenuation of pulmonary
IR injury: when using recombinant human vimentin, leukocyte
adhesion to endothelial and platelet monolayers where blocked
on P-selectin-coated surfaces in vitro. In vivo, histologic findings
of acute lung injury decreased.
These data underscore the relevant role of the adhesion
molecule P-Selectin and its inhibition on pulmonary
endothelium for the attenuation of IR injury.
Immunotargeting of
Angiotensin-Converting Enzyme and
Antioxidant Enzymes Against Oxidative
Injury
Angiotensin-converting enzyme (ACE) was previously identified
as a cell-specific marker of endothelial injury (Atochina et al.,
1997). Atochina et al. (1997) showed that IR induces significant
elevation of ACE activity in the perfusate of isolated rat
lungs. In this context, ACE serves as a surface endothelial
antigen that drives leukocyte-mediated oxidative injury to
endothelial cells. Muzykantov (2000) have shown that applying
a monoclonal antibody against ACE serves as an affinity carrier
for targeting of catalase to the pulmonary endothelial cells
for specific augmentation of their anti-oxidative defense. The
antioxidative effect of the conjugation of this ACE antibody
to catalase has also been investigated and confirmed in vivo
by Nowak and co-workers in a rat lung ischemia model
(Nowak et al., 2007). They used the ACE monoclonal antibody
(MAb) 9B9 and showed a better function of the affected
lung but also decreased serum levels of endothelin-1 and
less levels of inducible nitric oxide synthase. The same group
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evaluated the treatment of IR-injured lung allografts with
conjugates of anti-ACE antibody with catalase (9B9-CAT) in
an experimental set up of hypothermic preservation. Lungs
that were conditioned with this antibody showed a significantly
higher catalase activity and an anti-oxidative status after cold
storage compared to the catalase treatment alone (Nowak
et al., 2010). Finally, these authors extended their research on
an anti-ACE catalase-binding antibody in a human model of
isolated perfused and ventilated lung resection (Nowak et al.,
2013) and thus provided a possibility of immunotargeting of
human pulmonary endothelium toward a therapeutic approach
in patients. Of note, in the research of antioxidant therapeutics
against endothelial injury by reactive oxygen species, catalase was
also conjugated to platelet/endothelial cell adhesion molecule-1
and was demonstrated in vitro as well as in vivo to have good
protective effects against endothelial oxidative stress, injury, and
lethality (Christofidou-Solomidou et al., 2003) (Figure 2). This
approach could be confirmed by Kozower et al. (2003). The
entire concept of vascular immunotargeting by a specific delivery
of therapeutic agents to endothelial cells and by modulating
enzymes conjugated with antibodies to endothelial surface
molecules has been nicely summarized in a review by Shuvaev
and Muzykantov (2011).
Taken together, these studies show that vascular
immunotargeting of anti-oxidative enzymes, specifically
conjugates to ACE, can effectively limit reactive oxygen
species–mediated IR injury of the lung.
Other Strategies to Protect the Vascular
Endothelium From Lung IR Injury
This subsection will consider more therapeutic strategies on
how to preserve and protect the vascular endothelium from
IR injury that do not fall into the scope of the above
described approaches (Figure 2). Erythropoietin (EPO) has
been shown to positively influence acute lung injury caused by
renal IR injury (Janmaat et al., 2010). EPO acts as the major
regulator of erythropoiesis by stimulating growth, preventing
apoptosis, and inducing differentiation of blood precursor cells.
An explanation for a beneficial effect on lung injury could
lie in the fact that endothelial cells express EPO receptors
and thereby respond to EPO. Zhu et al. (2019) found in a
model of remote lung injury induced by mouse renal injury
that EPO exerts protective functions by promoting endothelial
cell proliferation via the Janus Kinase-Signal Transducer and
Activator of Transcription 3 pathway, rather than exerting
antiapoptotic or anti-inflammatory mechanisms.
Sharma et al. (2018) analyzed the role of pannexin-1 (Panx1), a
channel-forming glycoprotein that mediates signaling in vascular
endothelium and plays amajor role in the initiation of endothelial
permeability, edema, leukocyte trafficking, and inflammation
during lung IR injury. In an in vivo mouse lung hilar ligation
model, authors found that endothelial pannexin 1 contributes
to IR of the lung. Moreover, their results demonstrate a novel
role of endothelial Panx1 channels in the regulation of vascular
inflammation after lung IR: when blocking Panx1-mediated ATP
release by Panx1 inhibitors, lung IR injury could be attenuated.
The inhibition of the adhesion of leukocytes and platelets
to the endothelium was targeted in a study by Hashimoto and
the thoracic research group at Toronto General Hospital. Their
report in a rat lung transplantmodel says that Diannexin V, which
is a homodimer of annexin V, ameliorates IR injury. Authors
administered Diannexin V to the donor before procuring the
lung and also to the recipient shortly after reperfusion and could
prove a significantly enhanced graft function and an improved
oxygenation. Amechanistic explanation for the observed benefits
was that Diannexin is designed to shield phosphatidylserine, to
prevent cell adhesion, to improve blood flow and to diminish
subsequent tissue injury (Hashimoto et al., 2016). Practically,
authors concluded to employ this compound at an early phase
after transplantation to the recipient.
The group around Chatterjee, Christy and Fisher, all
renowned scientists in shear stress-related mechanosignaling
research in lung ischemia provided an excellent review
article showing that the mechanosignaling cascade during
lung IR injury is initiated by a mechanosensing complex,
transmitted by endothelial cell membrane depolarization
due to closure of KATP (ATP-sensitive potassium channels)
channels, resulting in activation of NADPH oxidase, NOX2
with generation of ROS and increased intracellular Ca2+
(Chatterjee et al., 2014). Authors point to an approach to
prevent the mechanosignaling cascade by using a KATP
channel agonist to prevent endothelial cell membrane
depolarization. Although these agents are available for
this purpose, they have not yet been trialed clinically
(Chatterjee et al., 2014).
Viruses are used since long as gene delivery vectors to
treat diseases by therapeutic gene expression (Waehler et al.,
2007) (Figure 3). One of the most commonly investigated viral
vectors is the adeno-associated virus. As an immunotherapeutic
approach, McConnell et al. (2014) took advantage of such a
virus as a “trojan horse” that delivers silicon microparticles into
inflammation-associated endothelium where it is internalized
and subsequently releases therapeutic nanoparticles. The virus
than becomes free within the cytoplasm undergoing genetic
cargo to successfully transfer into the nucleus for transcription.
This kind of uptake is independent from cell receptors,
enabling access to not only endothelial cells. Authors, thus,
showed that whole organs can be genetically modified using
this particle platform as a technique for improving organ or
vessel transplant.
But also a non-viral gene transfer approach for the
preservation of IR-injured endothelium is possible and, beyond
that, provides several advantages over the commonly used viral
systems, such as lower immunogenicity, reduced inflammation,
and an overall better safety. Using this approach, Liu and
colleagues analyzed the role of Indoleamine-2,3-dioxygenase
(IDO) as a cytosolic enzyme possessing both immunemodulating
and antioxidant properties against lung transplant IR injury
(Figure 3). They delivered a human IDO (hIDO)-expressing
plasmid driven by an endothelial cell-specific endothelin-1
promoter into rat donor lungs and found that hIDO expression
specifically enhanced in endothelial cells within lung grafts
and prevented endothelial cell apoptosis, reduced vascular
permeability and leukocyte extravasation in vivo (Liu et al., 2019).
In vitro, they showed that increased IDO activity in endothelial
cells protected its mitochondrial function and ultrastructure from
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oxidative stress through stabilization of the intracellular redox
status (Liu et al., 2019) (Figure 3). Authors, thus, presented a
strategy of non-viral gene transfer for the protection of lung
endothelium, at the same time avoiding the toxic effects of a
traditional viral therapy.
Another promising treatment tool is siRNA (Figure 2). By
using this highly specific technology, an organ-specific gene
transfer can be achieved even without the need of viral vectors
or other transfection agents. Zhang et al. (2004) showed that by
intranasal delivery of siRNA into mouse IR-injured endothelial
cells, apoptosis can be attenuated via an overexpression of Heme
oxygenase-1 (HO-1), an important cytoprotective enzyme in IR
injury. This concept contributes to the identification of genes
that modulate IR-induced apoptosis with potential therapeutic
relevance. siRNA was also used to target adhesion molecules in
an in vitro work by Walker et al. (2011). They transfected human
lung microvascular endothelial cells with specific siRNA and
found that not only adhesion molecules on the endothelium were
decreased but also the adhering neutrophils were diminished
(Walker et al., 2011) (Figure 2).
Another drug delivery system to target IR-injury–mediated
reactive oxygen species in the vascular endothelium are
liposomes. Howard et al. (2014) designed endothelial-
targeted liposomes carrying a potent superoxide dismutase
(SOD)/catalase mimetic, EUK-134, antibody-targeted against
PECAM. The Ab/EUK/liposome conjugates bound to endothelial
cells and inhibited cytokine-induced inflammatory activation
in vitro (Figure 2); in vivo, they accumulated in lungs after
intravascular injection and protected against pulmonary edema
in endotoxin-challenged mice (Howard et al., 2014). The
advantage of this compound is that it is already in clinical use.
Oxidized phospholipids are known to enhance the endothelial
barrier by maintaining the endothelial cell-cell junctions.
Such a compound, OxPAPC, was shown to directly bind to
different cytoskeletal proteins thereby stabilizing the cytoskeletal
reorganization and endothelial cell barrier enhancement and,
thus, the vascular integrity (Birukova et al., 2014).
SUMMARY AND CONCLUSION
Maintenance of the integrity of the pulmonary vascular
endothelium is pivotal in order to protect from IR injury in lung
transplantation. A number of therapeutic strategies with strong
impact have been developed, among them are mediators against
ROS and inhibition of endothelial-related adhesion molecules to
mainly attenuate neutrophil transmigration into the pulmonary
tissue. But also very promising recent approaches, e.g., the
stabilization of the endothelial glycocalyx seems to be important
as this layer is the prominent interface between the blood
stream, its constituents, and the vascular endothelium. On the
other hand, novel developments such as the concept of the
inhibition of endothelial autophagy are promising, but needmore
experimental work in order to gain solid scientific evidence.
Finally, viral as well as non-viral strategies and siRNA treatment
approaches are emerging and seem fascinating. At the same
time, they have fewer side effects in contrast to immunotargeting
approaches. While the concept of liposome release is already
in clinical use, the majority of the other approaches did not
translate into clinics up to now. We can only speculate why
these approaches did not reach clinical application. One reason is
certainly that there is a clear need for more translational research
to clarify a definite role for these therapeutic tools in endothelial
preservation. Another reason could lie in the fact that there is
more support needed from respective pharmacological industrial
partners to apply these measures broadly into the clinic. The
future, in my eyes, lies in making major efforts in the prevention
of the initiating damaging effects of IR injury such as preserving
the glycocalyx, rather than the treatment of the endothelium that
is already IR-injured. The impact of lung endothelium IR-injury
on the development and incidence of transplant rejection and
overall transplant outcome is undoubted, therefore, major efforts
need to be taken to strengthen those promising experimental
therapeutic approaches and translate them into clinical trials.
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